Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Milestones in the Pompe Disease Market’s Growth Trajectory From 2025 To 2034?

In the past few years, the market size of Pompe disease has witnessed a consistent growth. It is anticipated that from a valuation of $1.74 billion in 2024, it will increase to $1.8 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 3.3%. The expansion during the historic period can be ascribed to factors such as heightened awareness and diagnosis, orphan drug recognition and related incentives, international collaborations and research initiatives, patient advocacy, alongside the presence of supportive groups.

We can expect a significant surge in the size of the Pompe disease market in the coming years. It is predicted to reach$2.31 billion by 2029, with a compound annual growth rate (CAGR) of 6.5%. Several factors for this anticipated increase during the forecast period are persistent R&D efforts, the expansion of newborn screening programs, advancements in gene therapy, a rise in global funding for rare diseases, a patient-centered approach to drug development, enlargement of clinical trials and research initiatives, and a market focus on personalization in medicine. Key trends to notice during the forecast period would be the innovation of products, technological breakthroughs, setting up of patient support programs, increased use of telemedicine for managing patients, and partnerships to expand access programs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11906&type=smp

Which Primay Drivers Are Accelerating Growth in the Pompe Disease Market?

The escalations in occurrences of pompe disease are anticipated to fuel the expansion of the pompe disease market. Pompe disease, also referred to as glycogen storage disease type II or acid maltase deficiency, is an uncommon genetic disorder typified by the accumulation of glycogen (a complex carbohydrate) in various body tissues, predominantly in muscles and organs. Therapy options for pompe disease encompass protein replacement therapy, alglucosidase alfa, and Nexviazyme for intravenous infusion. The upswing in pompe disease instances is contributing to the upward trend in the pompe disease market. For example, in June 2022, as per the European Medicines Agency Highlights, a body based in Europe, there are approximately 224 infantile-onset, 471 juvenile-onset, and 20,490 adult-onset individuals in Europe with mutations possibly leading to Pompe disease, based on the highest birth incidence of 11.6 per 100,000. Hence, the amplification in the rate of pompe disease is acting as a catalyst for the growth of the pompe disease market.

Which Primary Segments of the Pompe Disease Market Are Driving Growth and Industry Transformations?

The pompe diseasemarket covered in this report is segmented –

1) By Type: Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form, Other Types

2) By Diagnosis: Blood Test, Genetic Test, Prenatal Test, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral, Other routes Of administrations

4) By Therapy Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Gene Therapy, Other Therapies

5) By End Users: Hospitals Or Clinics, Pharmaceuticals, Researchers, Other End-Users

Subsegments:

1) By Classic Infantile Form: Early-Onset Classic Pompe Disease; Severe Classic Pompe Disease

2) By Non-Classic Infantile Form: Mild Non-Classic Infantile Pompe Disease; Variants of Non-Classic Infantile Form

3) By Late-Onset Form: Adult-Onset Pompe Disease; Juvenile-Onset Pompe Disease

4) By Other Types: Asymptomatic Carriers; Other Rare Variants of Pompe Disease

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=11906&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Pompe Disease Market?# Market?

North America was the largest region in the pompe disease market in 2024. The regions covered in the pompe disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Pompe Disease Industry Dynamics?

Amongst current trends in the Pompe disease market, product innovations are gaining significant traction. Market leaders are leveraging these innovations to maintain their competitiveness. To illustrate, in September 2023, US biopharmaceutical firm, Amicus Therapeutics secured the approval of the U.S. Food and Drug Administration (FDA) for Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) 65 mg capsules. These two therapies have been specially created for adults with late-onset Pompe disease (LOPD) who weigh 40kg or above. The unique combination of Pombiliti, a recombinant human GAA enzyme (rhGAA) designed for better absorption into muscle cells, and Opfolda, which stabilizes the enzyme in the blood, emphasizes the importance of scientific and medical progress. The FDA’s go-ahead further cements this fact.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pompe-disease-global-market-report

What Parameters Are Used to Define the Pompe Disease Market?

Pompe disease is a genetic condition in which a complex sugar called glycogen accumulates in the body’s cells. The situation is caused by a lack of an enzyme known as acid alfa glucosidase (GAA), which breaks down complex carbohydrates in the body.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11906

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model